Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where M Kuehne is active.

Publication


Featured researches published by M Kuehne.


Europace | 2017

Incidence of new-onset atrial fibrillation after cavotricuspid isthmus ablation for atrial flutter

Umut Celikyurt; Sven Knecht; M Kuehne; Tobias Reichlin; Aline Muehl; Florian Spies; Stefan Osswald; Christian Sticherling

AimsnIn patients with cavotricuspid isthmus (CTI) ablation for atrial flutter (AFL), the decision to hold oral anticoagulation (OAC) often becomes an issue. The purpose of this study was to describe the incidence of the development of atrial fibrillation (AF) after CTI ablation in patients with documented AFL with and without a previous history of AF and to identify risk predictors for the occurrence of AF after CTI.nnnMethods and resultsnWe included 364 consecutive patients undergoing successful CTI ablation. Thereof, 230 patients (170 male; age 66u2009±u200911 years) had AFL only (AFL group) and 134 patients (94 male; age 65u2009±u200911 years) had AFL and previously documented AF (AFL and AF group). Over a mean follow-up of 22u2009±u200920 months, 163 (71%) patients in the AFL group and 67 (50%) patients in the AFL and AF groups had no documentation of a recurrent atrial arrhythmia (Pu2009<u20090.001). AF developed in 51 patients (22%) in the AFL group and in 57 (43%) patients in the AFL and AF groups (Pu2009<u20090.001). In patients without history of AF, left atrial diameter was the only predictor of development of AF (HR 1.058 [95%CI 1.011-1.108], Pu2009=u20090.016). Multivariate analysis of the total population identified history of AF (HR 1.918 [95%CI 1.301-2.830], Pu2009=u20090.001) and BMI as predictors for AF development (HR 1.052 [95%CI 1.012-1.093], Pu2009=u20090.011).nnnConclusionnOur results indicate that new-onset AF develops in a significant proportion of patients undergoing CTI for AFL. One should therefore be careful to withhold OAC. Furthermore, pulmonary vein isolation should be considered in conjunction with CTI, particularly in patients with previously documented AF.


Journal of the American Heart Association | 2017

Prohormones in the Early Diagnosis of Cardiac Syncope

Patrick Badertscher; Thomas Nestelberger; Jeanne du Fay de Lavallaz; Martin Than; Beata Morawiec; Damian Kawecki; Òscar Miró; Beatriz López; F. Javier Martín-Sánchez; José Bustamante; Nicolas Geigy; Michael Christ; Salvatore Di Somma; W. Frank Peacock; Louise Cullen; François Sarasin; Dayana Flores; Michael Tschuck; Jasper Boeddinghaus; Raphael Twerenbold; Karin Wildi; Zaid Sabti; Christian Puelacher; Maria Rubini Gimenez; Nikola Kozhuharov; Samyut Shrestha; Ivo Strebel; Katharina Rentsch; Dagmar I. Keller; Imke Poepping

Background The early detection of cardiac syncope is challenging. We aimed to evaluate the diagnostic value of 4 novel prohormones, quantifying different neurohumoral pathways, possibly involved in the pathophysiological features of cardiac syncope: midregional–pro‐A‐type natriuretic peptide (MRproANP), C‐terminal proendothelin 1, copeptin, and midregional‐proadrenomedullin. Methods and Results We prospectively enrolled unselected patients presenting with syncope to the emergency department (ED) in a diagnostic multicenter study. ED probability of cardiac syncope was quantified by the treating ED physician using a visual analogue scale. Prohormones were measured in a blinded manner. Two independent cardiologists adjudicated the final diagnosis on the basis of all clinical information, including 1‐year follow‐up. Among 689 patients, cardiac syncope was the adjudicated final diagnosis in 125 (18%). Plasma concentrations of MRproANP, C‐terminal proendothelin 1, copeptin, and midregional‐proadrenomedullin were all significantly higher in patients with cardiac syncope compared with patients with other causes (P<0.001). The diagnostic accuracies for cardiac syncope, as quantified by the area under the curve, were 0.80 (95% confidence interval [CI], 0.76–0.84), 0.69 (95% CI, 0.64–0.74), 0.58 (95% CI, 0.52–0.63), and 0.68 (95% CI, 0.63–0.73), respectively. In conjunction with the ED probability (0.86; 95% CI, 0.82–0.90), MRproANP, but not the other prohormone, improved the area under the curve to 0.90 (95% CI, 0.87–0.93), which was significantly higher than for the ED probability alone (P=0.003). An algorithm to rule out cardiac syncope combining an MRproANP level of <77 pmol/L and an ED probability of <20% had a sensitivity and a negative predictive value of 99%. Conclusions The use of MRproANP significantly improves the early detection of cardiac syncope among unselected patients presenting to the ED with syncope. Clinical Trial Registration URL: http://www.clinicaltrials.gov. Unique identifier: NCT01548352.


Swiss Medical Weekly | 2017

Design of the Swiss Atrial Fibrillation Cohort Study (Swiss-AF): structural brain damage and cognitive decline among patients with atrial fibrillation

David Conen; Nicolas Rodondi; Andreas Mueller; Juerg H. Beer; Angelo Auricchio; Peter Ammann; Daniel Hayoz; Richard Kobza; Giorgio Moschovitis; Dipen Shah; Juerg Schlaepfer; Jan Novak; Marcello Di Valentino; Paul Erne; Christian Sticherling; Leo H. Bonati; Georg Ehret; Laurent Roten; Urs Fischer; Andreas U. Monsch; Christoph Stippich; Jens Wuerfel; Matthias Schwenkglenks; M Kuehne; Stefan Osswald

BACKGROUNDnSeveral studies found that patients with atrial fibrillation (AF) have an increased risk of cognitive decline and dementia over time. However, the magnitude of the problem, associated risk factors and underlying mechanisms remain unclear.nnnMETHODSnThis article describes the design and methodology of the Swiss Atrial Fibrillation (Swiss-AF) Cohort Study, a prospective multicentre national cohort study of 2400 patients across 13 sites in Switzerland. Eligible patients must have documented AF. Main exclusion criteria are the inability to provide informed consent and the presence of exclusively short episodes of reversible forms of AF. All patients undergo extensive phenotyping and genotyping, including repeated assessment of cognitive functions, quality of life, disability, electrocardiography and cerebral magnetic resonance imaging. We also collect information on health related costs, and we assemble a large biobank. Key clinical outcomes in Swiss-AF are death, stroke, systemic embolism, bleeding, hospitalisation for heart failure and myocardial infarction. Information on outcomes and updates on other characteristics are being collected during yearly follow-up visits.nnnRESULTSnUp to 7 April 2017, we have enrolled 2133 patients into Swiss-AF. With the current recruitment rate of 15 to 20 patients per week, we expect that the target sample size of 2400 patients will be reached by summer 2017.nnnCONCLUSIONnSwiss-AF is a large national prospective cohort of patients with AF in Switzerland. This study will provide important new information on structural and functional brain damage in patients with AF and on other AF related complications, using a large variety of genetic, phenotypic and health economic parameters.


BMC Cardiovascular Disorders | 2017

Case report: electrical storm during induced hypothermia in a patient with early repolarization

Patrick Badertscher; M Kuehne; Beat Schaer; Christian Sticherling; Stefan Osswald; Tobias Reichlin

BackgroundPopulation based studies showed an association of early repolarization in the electrocardiogram (ECG) and a higher rate of sudden cardiac death presumably due to ventricular fibrillation. The triggers for ventricular fibrillation in patients with early repolarization are not fully understood.Case presentationWe describe the case of a young patient with a survived ventricular fibrillation arrest while asleep followed by multiple episodes of recurrent ventricular fibrillation. The admission ECG showed an early repolarization pattern with substantial J-point elevation in most of the ECG-leads. After initiation of a hypothermia protocol, the patient developed an electrical storm with multiple ventricular fibrillation episodes requiring multiple cardioversions. Intravenous isoproterenol infusion successfully suppressed the malignant arrhythmia.ConclusionHypothermia appears proarrhythmic in patients with early repolarization and may trigger ventricular fibrillation. This knowledge is particularly important when initiating temperature management protocols in patients after a survived cardiac arrest. During the acute phase of an early repolarization associated electrical storm, isoproterenol is the most effective treatment suppressing the ventricular fibrillation-inducing premature ventricular complexes at higher heart rates.


Archive | 2018

Management of acute presentation with atrial fibrillation - rate control

Christian Sticherling; M Kuehne


European Heart Journal | 2018

1358Prevalence of silent vascular brain lesions among patients with atrial fibrillation and no known history of stroke

S Blum; M Kuehne; Nicolas Rodondi; A Mueller; Peter Ammann; Giorgio Moschovitis; Richard Kobza; Juerg Schlaepfer; P Meyre; Leo H. Bonati; Georg B. Ehret; Christian Sticherling; Matthias Schwenkglenks; Stefan Osswald; David Conen


European Heart Journal | 2018

P980Physical activity and outcome in patients with atrial fibrillation

Roman Brenner; Stefanie Aeschbacher; Steffen Blum; P. Meyre; Peter Ammann; Paul Erne; Giorgio Moschovitis; M. Di Valentino; D Shah; Juerg Schlaepfer; M Kuehne; Christian Sticherling; Stefan Osswald; David Conen


European Heart Journal | 2018

P3873Introduction of leadless transcatheter intracardiac pacing: assessing the initial learning curve

Tobias Reichlin; Sven Knecht; F. Spies; Beat Schaer; Stefan Osswald; Christian Sticherling; M Kuehne


Europace | 2018

P297Impact of contact force sensing technology on catheter ablation success of idiopathic ventricular arrhythmias originating from the outflow tracts

R Ebrahimi; M Kuehne; Sven Knecht; Florian Spies; Beat Schaer; Stefan Osswald; Christian Sticherling; Tobias Reichlin


Europace | 2018

P453Prospective Validation of Diagnostic and Prognostic Syncope Scores in the Emergency Department

Patrick Badertscher; J Du Fay De Lavallaz; Thomas Nestelberger; R Isenrich; Ivo Strebel; Zaid Sabti; Christian Puelacher; M Kuehne; Christian Mueller; Tobias Reichlin

Collaboration


Dive into the M Kuehne's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Peter Ammann

University of St. Gallen

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

David Conen

Population Health Research Institute

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge